Julie O’Neal
YOU?
Author Swipe
View article: Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Batch specific co-expression analysis.
View article: Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
List of recurrent mutations with potential utility as neoantigens
View article: Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
View article: Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.
View article: Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
supplementary figures
View article: Ablation of CD38 in Multiple Myeloma Cells Leads to an Aggressive Phenotype in a Mouse Xenograft Model
Ablation of CD38 in Multiple Myeloma Cells Leads to an Aggressive Phenotype in a Mouse Xenograft Model Open
Multiple myeloma (MM) is a plasma cell malignancy characterized by bone pain and organ failure. A major challenge in treating MM is therapeutic resistance. CD38-targeted immunotherapies, such as daratumumab, have significantly improved out…
View article: Efficient creation and characterization of multi-kilobase knockins by CRISPR/Cas9 and multiple rAAVs
Efficient creation and characterization of multi-kilobase knockins by CRISPR/Cas9 and multiple rAAVs Open
We report the successful creation of multi-kilobase knockin mice and cell lines using three rAAV donors and CRISPR/Cas9 via consecutive homology-directed repair and reliable generation of over 120 KI mice with rAAV donors. For comprehensiv…
View article: Table S6 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S6 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.
View article: Table S1 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S1 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
View article: Table S3 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S3 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Batch specific co-expression analysis.
View article: Table S6 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S6 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.
View article: Table S4 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S4 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.
View article: Table S2 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S2 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
View article: Supplementary Figures from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Supplementary Figures from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
supplementary figures
View article: Table S2 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S2 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
View article: Table S3 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S3 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Batch specific co-expression analysis.
View article: Data from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Data from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Multiple myeloma (MM) is a highly refractory hematological cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone m…
View article: Supplementary Figures from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Supplementary Figures from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
supplementary figures
View article: Table S5 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S5 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
List of recurrent mutations with potential utility as neoantigens
View article: Table S4 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S4 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.
View article: Table S5 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S5 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
List of recurrent mutations with potential utility as neoantigens
View article: Table S1 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
Table S1 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
View article: Traversing the bench to bedside journey for iNKT cell therapies
Traversing the bench to bedside journey for iNKT cell therapies Open
Invariant natural killer T (iNKT) cells are immune cells that harness properties of both the innate and adaptive immune system and exert multiple functions critical for the control of various diseases. Prevention of graft-versus-host disea…
View article: #15. Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma
#15. Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma Open
View article: Anti-myeloma efficacy of BCMA CAR-iNKT is enhanced with a long-acting IL-7, rhIL7hyFc
Anti-myeloma efficacy of BCMA CAR-iNKT is enhanced with a long-acting IL-7, rhIL7hyFc Open
View article: EXTH-02. A TERT-SPECIFIC TCR-LIKE ANTIBODY CAR T CELL APPROACH FACILITATES KILLING OF GLIOBLASTOMA
EXTH-02. A TERT-SPECIFIC TCR-LIKE ANTIBODY CAR T CELL APPROACH FACILITATES KILLING OF GLIOBLASTOMA Open
Glioblastoma (GBM) is a difficult form of brain cancer to treat as GBM cells utilize various strategies to evade host immune responses. Prior studies have shown autologous cytotoxic T cells (CTL) modified to express chimeric antigen recept…
View article: Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc Open
Multiple myeloma (MM), a malignancy of mature plasma cells, remains incurable. B-cell maturation antigen (BCMA) is the lead protein target for chimeric antigen receptor (CAR) therapy because of its high expression in most MM, with limited …
View article: Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
View article: Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.
View article: Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma Open
supplementary figures